Abstract |
The combination therapy with pegylated interferon alpha and ribavirin has increasingly prescribed for chronic hepatitis C. Although many side effects of interferon such as flu-like symptoms, gastrointestinal and neuropsychiatric symptoms are well known, only several cases of interferon-induced pulmonary toxicity have been reported. Interferon-induced pulmonary toxicity usually develops from 2 weeks to 12 weeks after treatment for HCV infection. Diagnosis is commonly based on clinical findings such as a dry cough, dyspnea, hypoxemia, and a restrictive pattern in pulmonary function testing, bilateral diffuse parenchymal infiltrations, histopathological findings of interstitial pneumonitis, and exclusion of any other causative agents. Prompt withdrawal of the drug is the cornerstone of treatment. We report a case of PEG-IFN alpha-2a induced pulmonary toxicity in a 50-year-old male patient with hepatitis C. To our knowledge, this is the first case of pegylated interferon alpha-2a induced pulmonary toxicity in Korea.
|
Authors | Byoung Kwan Son, Joo Hyun Sohn, Tae Yeob Kim, Yoon Kyung Park, Yong Chul Jeon, Dong Soo Han |
Journal | The Korean journal of hepatology
(Korean J Hepatol)
Vol. 13
Issue 1
Pg. 103-7
(Mar 2007)
ISSN: 1738-222X [Print] Korea (South) |
PMID | 17380081
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antiviral Agents
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
- Polyethylene Glycols
- Ribavirin
- peginterferon alfa-2a
|
Topics |
- Antiviral Agents
(administration & dosage, adverse effects, therapeutic use)
- Hepatitis C, Chronic
(drug therapy)
- Humans
- Interferon alpha-2
- Interferon-alpha
(administration & dosage, adverse effects, therapeutic use)
- Lung Diseases
(chemically induced, diagnosis, pathology)
- Male
- Middle Aged
- Polyethylene Glycols
(administration & dosage, adverse effects, therapeutic use)
- Recombinant Proteins
- Ribavirin
(administration & dosage, therapeutic use)
- Treatment Outcome
|